Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
VRCA · Nasdaq · United States · Pharmaceutical Preparations
In shortVerrica Pharmaceuticals Inc. is loss-making, burns cash and holds more cash than debt, with revenue growing (+370.2% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -34.2% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -50.3% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -240.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -38.9% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.59× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -1.57× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -19.42 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -49.5% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 4 | 17/100 |
| Revenue growth volatility | 192.5% | 0/100 |
| Operating margin volatility | 522.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 57.9% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 12 | 9 | 5.1 | 7.6 | 36 |
| Cost of revenue | – | – | 0.5 | 2.6 | – |
| Gross profit | – | – | 4.6 | 5 | – |
| Research & development | 16 | 12 | 20 | 12 | 8.9 |
| Selling, general & admin | – | 17 | 47 | 59 | 35 |
| Operating income | (31) | (21) | (66) | (66) | (12) |
| Interest expense | 4.3 | 2.2 | 4 | 9.4 | 7.7 |
| Income tax | – | 0 | 0 | 0 | 0 |
| Net income | (35) | (24) | (67) | (77) | (18) |
| Diluted EPS | −$1.30 | −$0.72 | −$1.48 | −$14.78 | −$1.68 |
| Diluted shares (millions) | 27 | 34 | 45 | 5.2 | 11 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
−19.42 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026